sb 216763 has been researched along with pomalidomide in 1 studies
| Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) | Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) |
|---|---|---|---|---|---|
| 342 | 0 | 225 | 623 | 121 | 552 |
| Protein | Taxonomy | sb 216763 (IC50) | pomalidomide (IC50) |
|---|---|---|---|
| DNA damage-binding protein 1 | Homo sapiens (human) | 2.1 | |
| Protein cereblon | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, F; Jiang, X; Liu, X; Sun, H; Wang, Y; Xu, J; Xu, K; Zhou, J | 1 |
1 other study(ies) available for sb 216763 and pomalidomide
| Article | Year |
|---|---|
PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases.
Topics: Animals; Enzyme Inhibitors; Glycogen Synthase Kinase 3 beta; HT29 Cells; Humans; Models, Molecular; Neurodegenerative Diseases; PC12 Cells; Proteolysis; Rats; Small Molecule Libraries | 2021 |